The multi-faceted antiviral nature of TBK1 make it a very promising therapeutic target to limit viral replication and spread; thus, additional studies must be done to further characterize in vivo use of TBK1-activating agents to limit CVB infection and subsequent viral disease. The gene discussed is TBK1; the disease is viral infectious disease.